Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Eyes First-To-Market Opportunity In Alopecia

Executive Summary

Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.

You may also be interested in...



Concert Looks To Phase III In Alopecia Areata, Ahead Of Pfizer’s JAK Inhibitor

Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.

10 Things For Pfizer's New CEO To Worry About

Albert Bourla will face opportunities and potential pitfalls.

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123862

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel